{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Squamous+Cell+Carcinoma+Stage+IV",
    "query": {
      "condition": "Lung Squamous Cell Carcinoma Stage IV"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 193,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Squamous+Cell+Carcinoma+Stage+IV&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T05:44:46.706Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04954885",
      "title": "Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lung Non-Squamous Non-Small Cell Carcinoma",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Physical Performance Testing",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-05-18",
      "completion_date": "2022-10-12",
      "has_results": false,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04954885"
    },
    {
      "nct_id": "NCT00509366",
      "title": "Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin & Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin & Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel & Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed & Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2007-05",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-08-28",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 8,
      "location_summary": "Durham, North Carolina • Henderson, North Carolina • Laurinburg, North Carolina + 5 more",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Henderson",
          "state": "North Carolina"
        },
        {
          "city": "Laurinburg",
          "state": "North Carolina"
        },
        {
          "city": "Lumberton",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509366"
    },
    {
      "nct_id": "NCT01323062",
      "title": "Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Bavituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2011-05",
      "completion_date": "2018-10-01",
      "has_results": false,
      "last_update_posted_date": "2018-12-04",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323062"
    },
    {
      "nct_id": "NCT07155187",
      "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Telisotuzumab Adizutecan",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 430,
      "start_date": "2025-12-10",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 8,
      "location_summary": "Springdale, Arkansas • Rockledge, Florida • Saint Louis Park, Minnesota + 5 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Rockledge",
          "state": "Florida"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07155187"
    },
    {
      "nct_id": "NCT04670445",
      "title": "Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage IV Melanoma",
        "Advanced Lung Cancer",
        "Stage IV Non-Small Cell Lung Cancer",
        "Unresectable Non-Small Cell Lung Carcinoma",
        "Unresectable Stage III Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer Extensive Stage",
        "Stage IV Merkel Cell Carcinoma",
        "Stage IV Cutaneous Squamous Cell Carcinoma",
        "Stage IV Basal Cell Carcinoma",
        "Stage IV Breast Cancer",
        "Stage IV Colorectal Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Esophageal Cancer",
        "Stage IV Hepatocellular Cancer",
        "Stage IV Renal Cell Carcinoma",
        "Stage IV Bladder Cancer",
        "Stage IV Head and Neck Squamous Cell Carcinoma",
        "Stage IV Cervical Cancer",
        "Stage IV Endometrial Cancer",
        "Stage IV Mesothelioma",
        "Immunotherapy",
        "Immune Checkpoint Inhibitors"
      ],
      "interventions": [
        {
          "name": "Educational Video and QPL List",
          "type": "OTHER"
        },
        {
          "name": "Usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2021-01-23",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04670445"
    },
    {
      "nct_id": "NCT00897442",
      "title": "Collecting Tumor Samples From Patients With Gynecological Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Borderline Ovarian Clear Cell Tumor",
        "Borderline Ovarian Serous Tumor",
        "Cervical Adenocarcinoma",
        "Cervical Adenosquamous Carcinoma",
        "Cervical Small Cell Carcinoma",
        "Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Childhood Embryonal Rhabdomyosarcoma",
        "Childhood Malignant Ovarian Germ Cell Tumor",
        "Endometrioid Stromal Sarcoma",
        "Gestational Trophoblastic Tumor",
        "Malignant Mesothelioma",
        "Malignant Ovarian Epithelial Tumor",
        "Melanoma",
        "Neoplasm of Uncertain Malignant Potential",
        "Ovarian Brenner Tumor",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Paget Disease of the Vulva",
        "Recurrent Cervical Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Recurrent Vaginal Carcinoma",
        "Recurrent Vulvar Carcinoma",
        "Stage I Ovarian Cancer",
        "Stage I Uterine Corpus Cancer",
        "Stage I Vaginal Cancer",
        "Stage I Vulvar Cancer",
        "Stage IA Cervical Cancer",
        "Stage IA Fallopian Tube Cancer",
        "Stage IA Ovarian Cancer",
        "Stage IA Ovarian Germ Cell Tumor",
        "Stage IB Cervical Cancer",
        "Stage IB Fallopian Tube Cancer",
        "Stage IB Ovarian Cancer",
        "Stage IB Ovarian Germ Cell Tumor",
        "Stage IC Fallopian Tube Cancer",
        "Stage IC Ovarian Cancer",
        "Stage IC Ovarian Germ Cell Tumor",
        "Stage II Ovarian Cancer",
        "Stage II Uterine Corpus Cancer",
        "Stage II Vaginal Cancer",
        "Stage II Vulvar Cancer",
        "Stage IIA Cervical Cancer",
        "Stage IIA Fallopian Tube Cancer",
        "Stage IIA Ovarian Cancer",
        "Stage IIA Ovarian Germ Cell Tumor",
        "Stage IIB Cervical Cancer",
        "Stage IIB Fallopian Tube Cancer",
        "Stage IIB Ovarian Cancer",
        "Stage IIB Ovarian Germ Cell Tumor",
        "Stage IIC Fallopian Tube Cancer",
        "Stage IIC Ovarian Cancer",
        "Stage IIC Ovarian Germ Cell Tumor",
        "Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor",
        "Stage III Cervical Cancer",
        "Stage III Uterine Corpus Cancer",
        "Stage III Vaginal Cancer",
        "Stage III Vulvar Cancer",
        "Stage IIIA Fallopian Tube Cancer",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Ovarian Germ Cell Tumor",
        "Stage IIIA Primary Peritoneal Cancer",
        "Stage IIIB Fallopian Tube Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Ovarian Germ Cell Tumor",
        "Stage IIIB Primary Peritoneal Cancer",
        "Stage IIIC Fallopian Tube Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Ovarian Germ Cell Tumor",
        "Stage IIIC Primary Peritoneal Cancer",
        "Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer",
        "Stage IV Uterine Corpus Cancer",
        "Stage IVA Cervical Cancer",
        "Stage IVA Vaginal Cancer",
        "Stage IVB Cervical Cancer",
        "Stage IVB Vaginal Cancer",
        "Stage IVB Vulvar Cancer",
        "Uterine Corpus Cancer",
        "Uterine Corpus Leiomyosarcoma",
        "Vulvar Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 275,
      "start_date": "1992-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 187,
      "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897442"
    },
    {
      "nct_id": "NCT00025285",
      "title": "Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 46,
      "start_date": "2001-11-01",
      "completion_date": "2004-09-29",
      "has_results": false,
      "last_update_posted_date": "2021-09-09",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 5,
      "location_summary": "Decatur, Illinois • Goldsboro, North Carolina • Winston-Salem, North Carolina + 2 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Goldsboro",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025285"
    },
    {
      "nct_id": "NCT05652868",
      "title": "Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NSCLC",
        "NSCLC Stage IV",
        "NSCLC Stage IIIB",
        "Non-Small Cell Lung Cancer",
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Advanced Non-Small Cell Lung Cancer",
        "Advanced Non-Small Cell Non-Squamous Lung Cancer"
      ],
      "interventions": [
        {
          "name": "MYTX-011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mythic Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 227,
      "start_date": "2023-03-23",
      "completion_date": "2025-11-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 17,
      "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 13 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05652868"
    },
    {
      "nct_id": "NCT01532089",
      "title": "Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EGFR Exon 19 Deletion Mutation",
        "EGFR NP_005219.2:p.L858R",
        "Lung Non-Squamous Non-Small Cell Carcinoma",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2012-03-16",
      "completion_date": "2020-08-18",
      "has_results": true,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 19,
      "location_summary": "La Jolla, California • Decatur, Illinois • Peoria, Illinois + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01532089"
    },
    {
      "nct_id": "NCT00002520",
      "title": "Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Lung Cancer",
        "Lymphoma",
        "Prostate Cancer",
        "Testicular Germ Cell Tumor",
        "Tobacco Use Disorder",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "nicotine",
          "type": "DRUG"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "19 Years to 120 Years"
      },
      "enrollment_count": 434,
      "start_date": "1990-12-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-06-10T05:44:46.706Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002520"
    }
  ]
}